Special drug use-results surveillance of Tafinlar/Mekinist (BRAF-mutation-positive advanced/recurrent solid tumors(excluding colorectal cancer), CDRB436I1401)

sato masayuki0 个研究点目标入组 90 人开始时间: 2024年2月8日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•1. Patients who have given written consent to cooperate in this surveillance
•2. For patients aged < 18 years at the start of treatment with the product, their legally authorized representative must have given written informed consent for cooperation in this surveillance prior to patient enrollment.
•3. Patients who start treatment with the product for BRAF-mutation-positive advanced/recurrent solid tumors (excluding colorectal cancer) after the approval of additional indications

•1.Patients who have received or are receiving a product containing the same ingredient as the product in any other study or research than this surveillance
•2.Patients with BRAF-mutation-positive malignant melanoma
•3.Patients with BRAF-mutation-positive non-small cell lung cancer
•4.Patients with BRAF-mutation-positive hairy cell leukemia

发起方

sato masayuki